Menier Alanazi

Dr. Menier Alanazi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MAMeshari M Aljohani
Meshari M Aljohani
AAAhmed Abu-Rayyan
Ahmed Abu-Rayyan
NHNadia Hussein
Nadia Hussein
FAFuad A. Alatawi
Fuad A. Alatawi
MAMenier Alanazi
Menier Alanazi
RARehab Abdelmonem
Rehab Abdelmonem

5 December 2018 in Molecules
Verified
Journal Article
Open access
PDF file
MAMenier Alanazi
Menier Alanazi
BABelal Alnajjar
Belal Alnajjar
MKMelati Khairuddean
Melati Khairuddean
Human Epidermal Growth Factor Receptor-1 (EGFR), a transmembrane tyrosine kinase receptor (RTK), has been associated with several types of cancer, including breast, lung, ovarian, and anal cancers. Thus, the receptor was targeted by a variety of therapeutic approaches for cancer treatments. A series of chalcone derivatives are among the most highly potent and selective inhibitors of EGFR described to date. A series of chalcone derivatives were proposed in this study to investigate the intermolecular interactions in the active site utilizing molecular docking and molecular dynamics simulations. After a careful analysis of docking results, compounds 1a and 1d were chosen for molecular dynamics simulation study. Extensive hydrogen bond analysis throughout 7 ns molecular dynamics simulation revealed the ability of compounds 1a and 1d to retain the essential interactions needed for the inhibition, especially MET 93. Finally, MM-GBSA calculations highlight on the capability of the ligands to bind strongly within the active site with binding energies of −44.04 and −56.6 kcal/mol for compounds 1a and 1d, respectively. Compound 1d showed to have a close binding energy with TAK-285 (−66.17 kcal/mol), which indicates a high chance for compound 1d to exhibit inhibitory activity, thus recommending to synthesis it to test its biological activity. It is anticipated that the findings reported here may provide very useful information for designing effective drugs for the treatment of EGFR-related cancer disease.

1 May 2023 in Biomass Conversion and Biorefinery
Verified
Journal Article
Closed access
PDF file
AKAli A. Keshk
Ali A. Keshk
AAAhmed Abu-Rayyan
Ahmed Abu-Rayyan
NHNadia Hussein
Nadia Hussein
MAMenier Alanazi
Menier Alanazi
SSS. Said
S. Said
KSKamel R. Shoueir
Kamel R. Shoueir

3 January 2023 in Biomass Conversion and Biorefinery
Verified
Journal Article
Closed access
PDF file
AKAli A. Keshk
Ali A. Keshk
NHNadia Hussein
Nadia Hussein
FAFahad M. Almutairi
Fahad M. Almutairi
MAMenier Alanazi
Menier Alanazi
SSS. Said
S. Said
Mohamed Ramadan ElAassarMohamed Ramadan ElAassar
Mohamed Ramadan ElAassar

14 June 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
NINoor Zafirah Ismail
Noor Zafirah Ismail
MKMelati Khairuddean
Melati Khairuddean
MAMenier Alanazi
Menier Alanazi
HAHasni Arsad
Hasni Arsad